Browsing Tag
NASDAQ LGVN
2 posts
Is this the biomarker breakthrough Longeveron Inc. needs to reach Phase 3?
Can biomarker-linked response boost laromestrocel’s Phase 3 prospects? Explore regulatory, financial, and industry implications.
Longeveron Inc. appoints Stephen H. Willard as CEO ahead of pivotal Phase 2b stem cell data
Find out why Longeveron Inc.’s CEO appointment comes at a critical clinical and financial moment and what it could mean for investors and regenerative medicine.